FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new derivatives of carbamoylurea of the general formula (I) 
where R1 means hydrogen atom or a lower alkyl; R2 means lower alkoxy-group, lower alkylamino-group, lower cycloalkyl, optionally substituted phenyl and phenyl can has a substituent taken from the group: amino-group, halogen atom, lower alkyl, halogenated lower alkyl or means pyrrolidinyl-group; R3 means optionally substituted phenyl where substituents are taken from the group: halogen atom, lower alkyl, halogenated lower alkyl, lower alkoxy-group, cyano-group, tetrazolyl, a residue of the formula -R5(CH2)nR6 where n = 0-3; R5 means a bond, -O-, -S- or -S(O)-; R6 is the group COOR7 where R7 means hydrogen atom, lower alkyl, lower alkenyl; R4 means optionally substituted phenyl and phenyl can has 1-3 substituents taken from the group: amino-group, lower alkyl, halogenated alkyl, halogen atom, lower alkoxy-group, cyano-group, C3-C7-cycloalkyl that can be substituted with lower alkyl, C1-C10-alkyl of direct or branched chain, optionally substituted heterocyclic group taken from piperidinyl, thienyl or its pharmaceutically acceptable salt. Invention describes a pharmaceutical composition based on compounds of the formula (I) used for treatment of patients with different diseases associated with gastrin receptors and/or CCK-B (cholecystokinin). EFFECT: enhanced effectiveness of compounds and composition. 9 cl, 1 tbl, 7 ex
